Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs, resulting in the submission of false claims to federal healthcare programs.
Pfizer settles Biohaven kickback case with DOJ for $60M
Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce prescriptions for its migraine drug Nurtec ODT. Read more here.
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT,
Pfizer Settles $59.7M Medicare Kickback Case Over Biohaven Practices
Pfizer (NYSE:PFE) has agreed to pay $59.7 million to resolve allegations that Biohaven Pharmaceuticals, acquired by Pfizer in October 2022, defrauded Medicare and other healthcare programs by offering kickbacks to
Pfizer to pay ~$60M to settle Medicare false claims
Pfizer (PFE), on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical (BHVN), has agreed to pay $59,746,277 to resolve allegations
Biohaven Ltd. (NYSE:BHVN) Receives $63.00 Average Price Target from Analysts
Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been assigned a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports.
Investor's Business Daily on MSN4mon
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
Biohaven stock is poised to retake its 200-day line Monday after the company's experimental drug slowed progression in a ...
Biohaven enters multi-target collaboration with Merus
Biohaven (BHVN) announced a multi-target collaboration with Merus (MRUS). This collaboration will co-develop three programs encompassing highly ...
Pharm Exec11d
Biohaven Details Pipeline Update At JP Morgan Conference
The company provided information about its upcoming oncology portfolio, along with developments from its MoDE platform.
What's Going On With Merus Stock Monday?
Under the agreement, Merus will receive an upfront payment and a licensing fee once the first antibody drug conjugate (ADC) ...